14″ February “2022” SOURCE: AL JAZEERA
Jiilka soo socda ee tallaalada ayaa bixin doona jawaab celin ballaadhan oo adag. Waxaa dheer, sababta ay muhiim u tahay in
Faafida COVID-19 ee uu sababay coronavirus-ka daran ee neef-mareenka (SARS-CoV-2) ayaa weli ah khatar caalami ah. Malaayiin qof ayaa u dhintay xanuunka qaar badana waxay ku sii socdaan calaamado socda muddo dheer ka dib markii ay nadiifiyeen caabuqa ugu horreeya. In kasta oo aynu hore ugu sii soconnay aqoontayada fayraska, oo hadda aynu haysanno dawooyin la xaqiijiyey inay waxtar u leeyihiin daawaynta, haddana waxa inoo hadhay dariiqo aannu mustaqbalka u hubinno tallaallada hadda la isticmaalo si looga hortago cudurrada halista ah ee fayraska.
XAYEEYSIIS
Samaynta tallaaladu aad bay u adag tahay abuurista tallaallada COVID-19-na waxay ahayd guul aan hore loo arag. Laakiin iyada oo qaybinta tallaallada hadda ay tahay in ay sii socoto adduunka oo dhan, waa in aan sidoo kale isha ku haynaa jiilka soo socda ee tallaallada kuwaas oo bixin doona jawaab-celin ballaaran oo ka sii adag difaaca.
Talaalka jiilka labaad ee COVID-19 waxay u baahan doonaan inay ku dhismaan guusha kuwa hadda jira. Halka tallaalada mRNA-ga ee aadka loo isticmaalo ay kiciyaan jawaabta difaaca ee borotiinka taranka ee SARS-CoV-2, waxaan dhawaan aragnay in isbedelada iyo kala duwanaanshiyaha cusub ay bedeli karaan qaab dhismeedka qaybtan fayraska, taasoo ka dhigaysa tallaalada waxtarka yar. Jiilka soo socda ee tallaalada waa in la sameeyaa iyada oo ujeedadu tahay in aan inaga ilaalino kala duwanaanshiyaha hadda iyo mustaqbalka, iyada oo aan loo eegin sida ay u faafaan ama fayras u yihiin.
Intaa waxaa dheer, tallaalada mustaqbalka waa inay awoodaan inay yareeyaan halista gudbinta fayraska kuwa la tallaalay. Tani waxay ka dhigan tahay inay u baahan doonaan inay awoodaan inay yareeyaan culeyska fayraska, badanaa iyagoo bilaabaya heerar sare oo ka hortag ah oo ka hortag ah oo beegsan kara fayraska ka hor inta uusan fursad u helin inuu ku bato gudaha guriga oo uu faafiyo. Waxaan sidoo kale u baahanahay in ka jawaab celinta difaacu ay noqoto mid sii raaga inta ugu macquulsan, taasoo la macno ah kuwa xoojiya, haddii loo baahdo, waa la kala fogayn karaa
Muhiimad ahaan, haddii aan rabno inaan si heer caalami ah uga hortagno masiibadaan, tallaalladu waxay u baahan yihiin inay noqdaan kuwo raqiis ah oo la heli karo dhammaan.
XAYEEYSIIS
Mid ka mid ah tallaalka ku jira horumarinta, kaas oo laga yaabo inuu caawiyo xallinta arrimahan qaarkood, waa tallaalka is-weynaynta ee shirkadda biotech ee Gritstone ee mRNA (SAM) ee COVID-19, oo lagu magacaabo GRT-R910. MRNA-yada is-xoojiyey waxay muujiyeen muujinta antigen-ka oo la xoojiyey iyo soosaarka antibody-ka ee qiyaas yar marka la barbar dhigo mRNA-ga caadiga ah, taasoo soo jeedinaysa in tignoolajiyadani ay hagaajin karto tallaalka. Waxay markaa u baahan doontaa qiyaaso hoose iyo suurtogal ahaan kuwa xoojinaya oo yar.
Tallaalka GRT-R910 waxa uu galayaa tijaabada wajiga 1 ee Boqortooyada Midowday. Iyo sidoo kale soo saarista unugyada difaaca jirka borotiinka sare, waxaa la rajeynayaa inay sidoo kale u keento jawaab celin difaac borotiinada kale ee uu fayrasku haysto. Gritstone wuxuu bayaan ku sheegay in GRT-R910 ay kicin karto jawaabo difaac adag, waara oo ballaaran oo ka dhan ah noocyada SARS-CoV-2
Our SAM COVID vaccine is designed to drive robust CD8+ T cell responses, in addition to strong neutralising antibody responses, offering the promise of longer-lasting immunity, especially in more vulnerable populations,” explained Andrew Allen, the CEO of Gritstone. “Additionally, since viral surface proteins like the spike protein are evolving and sometimes partially evading vaccine-induced immunity, we designed GRT-R910 to have broad therapeutic potential against a wide array of SARS-CoV-2 variants by also delivering highly conserved viral proteins that may be less prone to antigenic drift
XAYEEYSIIS
WHO waxay ugu baaqday shirkadaha dawooyinka iyo dawladaha inay wadaagaan aqoontooda patent-ka ah iyo tignoolajiyada tallaalka COVID-19 si wadamada dhaqaalahoodu hooseeyo ilaa dhexdhexaadka ah ay u soo saaraan. Waxaa jiray jawaab yar oo ka timid shirkadaha, laakiin shirkadda Koonfur Afrika ee tignoolajiyada bayoolajiga, Afrigen Biologics and Vaccines, ayaa sii waday oo soo saartay nooceeda tallaalka Moderna COVID-19. Shirkadda, oo ay dooratay WHO, waxay u dooratay Moderna tallaalka si ay u soo celiso maadaama macluumaad badan oo ku saabsan soo saarista tallaalku ay ku jireen qaybta dadweynaha. Sidoo kale, Moderna waxa ay ballan qaaday in aanay dhaqan galinayn shatigeeda inta lagu jiro aafada.
Waxaa la rajeynayaa in “Moderna mimic” cusub uu diyaar u noqon doono tijaabada wajiga 1 dhamaadka 2022. Waxaa sidoo kale socda shaqada si loo soo saaro tallaalka qiyaasta si loo qaybiyo kuwa aadka u baahan. WHO waxa ay rajaynaysaa in Afrigen uu u shaqeeyo sidii xarun oo uu u tababaro shirkadaha kale ee adduunka si ay u soo saaraan tallaalka. Waxa jira tillaabooyin badan oo badan oo loo baahan yahay ka hor inta aan tallaalkan la soo saarin si caalami ah, oo ay ku jiraan kuwa sharciga ah. Laakiin haddii ay shaqeyso, waxay nagu qaadi doontaa hal tallaabo oo ku dhow inaan meesha ka saarno ku tiirsanaanta waddamada saboolka ah ee waddamada hodanka ah tallaaladooda COVID-19.
SOURCE: AL JAZEERA
